CAR-T therapy containing 2 anti-BCMA single-domain antibodies resulted in high response and PFS rates, according to phase 1b results.
Anti-BCMA CAR T-cell therapy idecabtagene vicleucel demonstrated promising efficacy among patients with heavily pretreated and refractory MM.
Findings from this study support use of serial MRD monitoring during lenalidomide maintenance therapy to identify patients likely to benefit from prolonged treatment.
Novel treatment options are needed to improve outcomes for patients with TP53-mutated myeloid neoplasms.
Immunomodulator indoleamine-2,3-dioxygenase may be a promising predictor and therapeutic target for patients with higher-risk myelodysplastic syndromes.
Streamlined prescribing and reimbursement, patient education tools aim to overcome barriers to adoption of genetic testing.
Higher graft CD34+ cell content is linked to improved platelet and neutrophil recovery after high-dose therapy.
The new generation of cancer drugs behave quite differently than cytotoxic therapies, and that may mean phase 1 trials need to be updated.
Given the prevalence, the IWG-PM evaluated available evidence to determine whether SF3B1-mutated MDS should be recognized as a distinct disease subtype.
IL-6 blockade may have helped a patient with multiple myeloma recover from COVID-19, but larger studies are needed to prove efficacy.
Pooling data from physicians and patients appears to be an efficient way to answer urgent questions.
Guidance is provided regarding possible treatment plan alterations for older patients with multiple myeloma based on COVID-19 infection risk.
Darzalex Faspro is a new subcutaneous formulation that contains daratumumab, a CD38-directed cytolytic antibody, with hyaluronidase, an endoglycosidase.
Two studies characterize hematological recovery after CAR-T cell therapy.
The SKY92 MMprofiler assay evaluates the expression of 92 multiple myeloma-related genes.
New study compares published data from various treatment regimens for multiple myeloma, scoring them on efficacy, cost, and adverse effects.
In recent years, the NCCN has updated its clinical practice guidelines to include MRD assessment for MM, ALL, and CLL.
Researchers sought to determine whether second cancers associated with MPNs affect a patient’s prognosis, and whether cytoreductive or antiplatelet therapies affect outcomes.
The best bet for a new company hoping to deliver on a lofty promise to “remake medicine” could rely on drug repurposing.
One finding from this study was that VTE was more likely to occur at atypical sites in patients with myelofibrosis compared to those without the disease.